List of Excipients in Branded Drug MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE PRODUCT

« Back to Dashboard

Generic Drugs Containing MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE PRODUCT

Company	Ingredient	NDC	Excipient
SpecGx LLC	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	0406-0805	ALCOHOL
SpecGx LLC	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	0406-0805	ETHYLCELLULOSE
SpecGx LLC	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	0406-0805	FERRIC OXIDE YELLOW
SpecGx LLC	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate	0406-0805	FERROUS OXIDE

What are the Most Frequently-Used Excipients in MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE PRODUCT?

# Of NDCs	Excipient
1	ALCOHOL
1	ETHYLCELLULOSE
1	FERRIC OXIDE YELLOW
1	FERROUS OXIDE

Excipient Strategy and Commercial Opportunities for Mixed Amphetamine Salts

Last updated: September 27, 2026

Mixed amphetamine salts are an established stimulant platform with extensive generic competition in immediate-release and extended-release dosage forms. Commercial opportunity is concentrated in differentiated release profiles, pediatric usability, abuse-deterrence attributes, supply reliability, and lifecycle extensions rather than in the active ingredient itself.

The relevant active moieties are dextroamphetamine and levoamphetamine supplied through four salts: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate. This composition is used in immediate-release mixed amphetamine salts products such as Adderall and in extended-release products such as Adderall XR and Mydayis [1-3].

What is the pharmaceutical product and how does its salt composition affect excipient selection?

Mixed amphetamine salts are not a conventional single-compound API. The product contains multiple salt forms that collectively deliver amphetamine base in a defined ratio. That structure creates formulation issues involving content uniformity, hygroscopicity, dissolution, particle segregation, and dose proportionality.

Product type	Representative product	Release profile	Primary formulation challenge
Immediate release	Adderall tablets and generics	Rapid release	Uniformity, tablet robustness, taste and swallowability
Extended release	Adderall XR capsules and generics	Biphasic release	Reproducible delayed and immediate release
Extended release, longer duration	Mydayis capsules	Multi-pulse release	Extended exposure, food effect, capsule-fill uniformity
Alternative oral products	Potential orally disintegrating, chewable or liquid formats	Immediate or modified release	Taste masking, dose accuracy and abuse-risk controls

The salt mixture can be blended directly with conventional tablet excipients, but the formulation must control segregation between salts and excipients. Particle-size distribution, bulk density, electrostatic behavior and blending order are material process variables.

What excipients are used in mixed amphetamine salts products?

FDA labels identify inactive ingredients for approved products, but excipient selection varies by manufacturer, dosage form and release mechanism. Common excipient categories include fillers, binders, disintegrants, lubricants, glidants, film-coating agents and capsule-shell materials [1-4].

Excipient function	Candidate materials	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Controls tablet weight and manufacturability
Binder	Povidone, hydroxypropyl cellulose, pregelatinized starch	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improves appearance, identification and swallowability
Release-controlling polymer	Ethylcellulose, methacrylate copolymers, hypromellose derivatives	Controls diffusion and dissolution
Pellet or bead substrate	Sugar spheres, microcrystalline cellulose spheres	Supports multiparticulate extended release
Capsule shell	Gelatin or hydroxypropyl methylcellulose	Enables bead-filled delivery and dose flexibility

Excipient choice is constrained by the amphetamine dose, the required release profile and the need to avoid excessive release acceleration. Strongly acidic or alkaline microenvironments can affect dissolution behavior and may create stability concerns. Moisture control is also important because some salt forms and common excipients can alter water activity, powder flow or tablet hardness.

What excipient strategy is most suitable for immediate-release mixed amphetamine salts?

The immediate-release opportunity is primarily operational and user-experience driven. Basic tablets are difficult to differentiate once generic competition is established, but several formulation improvements remain commercially relevant.

Content uniformity and blend control

A low-dose stimulant product requires consistent distribution of the four salt components throughout the blend. A direct-compression platform can reduce processing steps, but wet or dry granulation may improve uniformity and flow where the API has unfavorable handling characteristics.

Potential controls include:

• Narrower API particle-size specifications.
• Pre-blending of the salt mixture before dilution.
• Ordered mixing with a high-surface-area carrier.
• Low-shear blending to reduce segregation.
• In-process near-infrared monitoring.
• Density matching between API particles and major excipients.

These measures are more likely to support process patents, manufacturing know-how and regulatory differentiation than composition-of-matter protection.

Pediatric and geriatric usability

A smaller tablet, scored tablet, chewable tablet or orally disintegrating tablet could target patients who have difficulty swallowing. The main technical barrier is taste. Amphetamine salts have an inherently bitter and pharmacologically active taste, so taste masking may require polymer coating, ion-exchange resin complexation or multiparticulate encapsulation.

A chewable or orally disintegrating product would need to demonstrate:

• Dose uniformity after partial administration.
• Acceptable disintegration time.
• Low residual bitterness.
• Stability under humidity exposure.
• No clinically meaningful change in exposure.
• Clear instructions against crushing or unintended manipulation.

Flavoring alone is unlikely to provide sufficient differentiation. A coated-particle system or resin-based taste-masking platform is more defensible.

Tablet robustness and packaging

A high-value immediate-release product can combine low tablet weight with high mechanical strength and low friability. Film coating can improve identification and reduce handling dust. Unit-dose blister packaging can support adherence, moisture protection and diversion controls, but it can increase packaging cost.

What excipient strategy is most suitable for extended-release products?

Extended-release mixed amphetamine salts have the strongest formulation opportunity because pharmacokinetic performance can be differentiated without changing the active moiety.

Adderall XR uses a capsule containing immediate-release and delayed-release bead populations. The delayed-release component uses a pH-dependent coating, creating a two-pulse profile [2]. Mydayis is designed for longer-duration delivery through a multiparticulate extended-release system [3].

Multiparticulate bead systems

Multiparticulate systems offer several commercial advantages:

• More consistent gastrointestinal distribution than a single matrix tablet.
• Lower sensitivity to local gastrointestinal conditions.
• Easier dose proportionality.
• Potential sprinkle administration.
• Separate control of immediate and delayed release.
• Greater flexibility in coating thickness and polymer selection.

The main risks are coating uniformity, dose dumping, food effects and the complexity of scale-up. Drug-layering and polymer-coating operations require tight control of spray rate, inlet temperature, atomization and bed moisture.

Polymer and coating selection

A commercial formulation can use combinations of:

• Immediate-release uncoated beads.
• Functional coatings based on methacrylate polymers.
• Ethylcellulose or other water-insoluble diffusion barriers.
• Pore-forming agents.
• Seal coats to reduce API-polymer interaction.
• Overcoats to improve handling and capsule filling.

The formulation must establish a reproducible relationship between coating weight gain and dissolution. A small change in coating thickness can shift the delayed-release pulse and alter total exposure.

Longer-duration delivery

A product that extends coverage into the late day may compete with existing extended-release stimulants, but the commercial claim must be supported by pharmacokinetic and clinical data. The key differentiation variables are:

• Time to initial exposure.
• Time to peak concentration.
• Duration above a defined pharmacodynamic threshold.
• Decline rate late in the dosing interval.
• Food-related variability.
• Sleep and appetite effects.
• Flexibility for pediatric dosing.

A longer duration alone is not sufficient. Prescribers may value smoother exposure and lower afternoon rebound more than a maximum duration claim.

What formulations are protected by patents and regulatory exclusivity?

The active salt composition is mature and has faced generic competition. Formulation protection is more relevant than active-ingredient protection.

Protection category	Relevance to mixed amphetamine salts
Composition of matter	Limited value for established salt mixtures
Drug-release formulation	High value for bead, pellet, matrix and pulse-release systems
Method of use	May cover treatment schedules, patient populations or dosing regimens
Manufacturing process	Can protect layering, coating, blending and scale-up methods
Device or packaging	Relevant to unit-dose systems and controlled dispensing
Taste masking	Relevant to chewable, liquid and orally disintegrating products
Polymers and excipient combinations	Potentially useful where the combination produces a defined dissolution profile
Data and regulatory exclusivity	Usually less durable than formulation patents for legacy products

Orange Book-listed patents must be assessed at the specific NDA and dosage-form level. Adderall IR, Adderall XR and Mydayis are separate regulatory products with different approval histories and patent records. A patent covering an extended-release capsule does not automatically block an immediate-release tablet, and a method-of-use patent may not prevent approval for an unclaimed indication [5].

Paragraph IV litigation risk is highest when a generic applicant challenges a listed formulation or method patent while seeking approval before expiration. Once multiple generic versions are approved, a new entrant generally needs a meaningful advantage in duration, dosage form, supply reliability or patient usability to support premium pricing.

When does mixed amphetamine salts lose exclusivity?

Immediate-release mixed amphetamine salts products have already entered the mature generic phase. Adderall XR also has established generic competition. Mydayis entered a later lifecycle stage because its extended-duration formulation was approved in 2017 [2,3].

Exclusivity analysis should separate four dates:

1. FDA regulatory exclusivity expiration.
2. Orange Book patent expiration.
3. Pediatric exclusivity expiration, if awarded.
4. Earliest commercially permitted generic launch date after litigation or settlement.

A later-expiring formulation patent can preserve commercial protection after regulatory exclusivity ends. Conversely, an unchallenged patent does not guarantee market protection if it is not listed, invalidated or avoided by a competing formulation.

Which commercial opportunities remain for excipient suppliers?

Excipient suppliers can capture value through formulation-enabling products rather than commodity excipients.

High-value opportunity areas

Taste-masking platforms

Coated particles, ion-exchange resins and functional polymers can support chewable, liquid and orally disintegrating dosage forms. The strongest commercial position would come from a platform that masks bitterness without delaying absorption or increasing dose variability.

Extended-release coating systems

Prequalified coating polymers, ready-to-use aqueous dispersions and process controls can shorten development timelines. Suppliers with scale-up data across fluid-bed equipment have an advantage.

Low-moisture direct-compression systems

A co-processed excipient that improves flow, compressibility and content uniformity could reduce manufacturing complexity for immediate-release tablets.

Sprinkle-compatible multiparticulates

Parents and caregivers may prefer a capsule that can be opened and sprinkled on soft food. The product must retain dose uniformity, prevent bead damage and preserve the release profile after administration.

Abuse-deterrence enabling excipients

Manipulation-resistant matrix systems, tamper-evident coatings and crush-resistant multiparticulates may support differentiation. For prescription stimulants, abuse-deterrence positioning must be based on demonstrated performance and appropriately limited claims.

Packaging-linked excipient systems

Moisture-scavenging packaging, unit-dose blister systems and light-protective materials can extend shelf life and reduce dispensing errors. These products can be paired with formulation changes but are generally easier to implement than a new dosage form.

How does the opportunity compare with other ADHD drug products?

Product class	Commercial maturity	Excipient opportunity	Main barrier
Immediate-release mixed amphetamine salts	Mature	Taste, pediatric use, manufacturing efficiency	Heavy generic competition
Extended-release mixed amphetamine salts	Established	Pulse release, duration, sprinkle delivery	Bioequivalence and patent risk
Methylphenidate extended release	Mature but fragmented	Osmotic, coated-bead and matrix systems	Numerous competing technologies
Lisdexamfetamine	Branded and generic transition	Taste, chewable delivery, manufacturing	Active prodrug and patent history
Nonstimulant ADHD products	Less dependent on stimulant excipients	Liquid, pediatric and sustained delivery	Different efficacy and prescribing profile

Mixed amphetamine salts remain attractive where manufacturers can offer a clear pharmacokinetic or administration benefit. Commodity substitution alone is unlikely to produce durable margins.

What manufacturing and intellectual-property barriers are most significant?

The primary barriers are process consistency, bioequivalence, controlled-substance compliance and patent clearance.

Manufacturing barriers

• Uniform distribution of multiple salt components.
• Stable granulation and compression behavior.
• Consistent polymer coating thickness.
• Prevention of bead fracture during capsule filling.
• Control of moisture and electrostatic charging.
• Reproducible dissolution across commercial batches.
• Secure handling and reconciliation of Schedule II material.

Intellectual-property barriers

• Release-profile patents.
• Multiparticulate coating claims.
• Specific polymer combinations.
• Sprinkle or capsule-opening administration claims.
• Pediatric dosing and method-of-use claims.
• Manufacturing claims covering drug layering or coating.
• Formulation patents tied to food-effect reduction or abuse deterrence.

A strong formulation estate should have multiple independent claim strategies. A single narrow dissolution claim is vulnerable to design-around. A more durable estate combines composition, process, release profile, dosage-form and method-of-use claims.

What FDA regulatory pathway applies to new mixed amphetamine salts formulations?

A generic product generally follows the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence. A materially different dosage form, delivery system or clinical use may require a 505(b)(2) application rather than a standard abbreviated application [6].

Product strategy	Likely pathway
Conventional immediate-release tablet equivalent	ANDA
Equivalent extended-release capsule	ANDA, subject to product-specific guidance
New chewable or orally disintegrating product	Potentially 505(b)(2)
New liquid with different excipient system	Potentially 505(b)(2)
New duration or release profile	Usually higher development and clinical burden
Abuse-deterrent formulation	NDA or 505(b)(2), depending on product changes and claims

FDA inactive-ingredient limits and route-specific safety data must be reviewed through the Inactive Ingredient Database and applicable product-specific guidance [4,7]. Excipient changes can affect bioequivalence even when the active salt ratio remains unchanged.

What generic launch scenarios exist?

Three scenarios are commercially realistic.

Low-cost immediate-release launch

This strategy uses standard excipients, conventional packaging and a mature manufacturing process. It offers the lowest development risk but faces the greatest price pressure.

Differentiated extended-release launch

A multiparticulate product with a distinct duration or dosing profile can support higher pricing. The principal risks are bioequivalence, clinical positioning and patent litigation.

Patient-centered lifecycle extension

A chewable, sprinkle, orally disintegrating or lower-swallowing-burden product can target pediatric and adherence-sensitive populations. The commercial opportunity depends on taste masking, label differentiation and payer acceptance.

Key Takeaways

• Mixed amphetamine salts are a mature active-ingredient platform; the strongest opportunities are formulation and delivery innovations.
• Immediate-release products offer limited differentiation unless they improve taste, pediatric usability, manufacturing economics or packaging.
• Extended-release multiparticulate systems provide the most defensible technical and commercial opportunity.
• Excipient selection should focus on content uniformity, moisture control, polymer coating performance and taste masking.
• Orange Book and Paragraph IV analysis must be performed separately for Adderall IR, Adderall XR, Mydayis and each generic dosage form.
• A durable patent estate should combine formulation, process, release-profile and method-of-use claims.
• FDA pathway selection depends on whether the proposed product is pharmaceutically equivalent or introduces a materially different dosage form or delivery profile.
• Excipient suppliers are best positioned in functional polymers, coated particles, co-processed direct-compression systems, taste masking and sprinkle-compatible multiparticulates.

FAQs

Can a new excipient create market exclusivity for a mixed amphetamine salts product?

An excipient alone rarely creates exclusivity. Protection is more credible when the excipient produces a claimed and reproducible release profile, taste-masking effect, stability result or manufacturing advantage.

Are mixed amphetamine salts suitable for an abuse-deterrent formulation?

They are technically suitable for tamper-resistant approaches, but the formulation must demonstrate resistance to crushing, extraction or other manipulation. Regulatory and commercial value depends on validated performance and permitted labeling claims.

Can a sprinkle capsule avoid the patents covering an extended-release stimulant?

It may, depending on the specific claims. A product can still infringe claims directed to coated beads, release timing, polymers, administration with food or capsule contents. Claim-by-claim analysis is required.

Which excipient platform is most attractive for pediatric mixed amphetamine salts?

Taste-masked multiparticulates are among the strongest options because they can support sprinkle, chewable or orally disintegrating administration while preserving dose flexibility.

Is a new mixed amphetamine salts liquid likely to compete with tablets?

A liquid can address swallowing and dose-adjustment needs, but it carries higher taste-masking, stability, measuring-device and abuse-diversion requirements. Its strongest market is likely pediatric or titration-focused rather than broad substitution.

References

1. U.S. Food and Drug Administration. (2023). Adderall prescribing information. FDA.
2. U.S. Food and Drug Administration. (2023). Adderall XR prescribing information. FDA.
3. U.S. Food and Drug Administration. (2023). Mydayis prescribing information. FDA.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
6. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. FDA.
7. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. FDA.